Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants

被引：31
作者：
Ricci, V
Peterson, ML
Rotschafer, JC
Wexler, H
Piddock, LJV [1 ]
机构：
[1] Univ Birmingham, Div Immun & Infect, Antimicrobial Agents Res Grp, Birmingham B15 2TT, W Midlands, England
[2] Univ Minnesota, Minneapolis, MN 55455 USA
[3] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2004年 / 48卷 / 04期
关键词：
D O I：
10.1128/AAC.48.4.1344-1346.2004
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Twelve laboratory mutants and 32 ciprofloxacin-resistant isolates of Bacteroides fragilis were examined for the mechanism(s) of fluoroquinolone resistance. Five mutants had mutations in gyrA. One mutant and two clinical isolates contained a mutation in gyrB. Eight mutants and five clinical isolates accumulated significantly less ciprofloxacin than did wild-type isolates; the mutants and clinical isolates were restored to wild-type characteristics when carbonyl cyanide m-chlorophenylhydrazone was used.
引用
收藏
页码：1344 / 1346
页数：3
相关论文
共 16 条
  • [1] Determination of minimum inhibitory concentrations
    Andrews, JM
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 : 5 - 16
  • [2] Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin
    Bachoual, R
    Dubreuil, L
    Soussy, CJ
    Tankovic, J
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (07) : 1842 - 1845
  • [3] Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli
    Bagel, S
    Hüllen, V
    Wiedemann, B
    Heisig, P
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) : 868 - 875
  • [4] Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals
    Everett, MJ
    Jin, YF
    Ricci, V
    Piddock, LJV
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) : 2380 - 2386
  • [5] Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones
    Griggs, DJ
    Marona, H
    Piddock, LJV
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (06) : 1403 - 1407
  • [6] Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli
    Heisig, P
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (04) : 879 - 885
  • [7] Active efflux of norfloxacin by Bacteroides fragilis
    Miyamae, S
    Nikaido, H
    Tanaka, Y
    Yoshimura, F
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) : 2119 - 2121
  • [8] A MATE family multidrug efflux transporter pumps out fluoroquinolones in Bacteroides thetaiotaomicron
    Miyamae, S
    Ueda, O
    Yoshimura, F
    Hwang, J
    Tanaka, Y
    Nikaido, H
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (12) : 3341 - 3346
  • [9] Ecological disturbances in intestinal microflora caused by clinafloxacin, an extended-spectrum quinolone
    Oh, H
    Nord, CE
    Barkholt, L
    Hedberg, M
    Edlund, C
    [J]. INFECTION, 2000, 28 (05) : 272 - 277
  • [10] Molecular cloning of the gyrA and gyrB genes of Bacteroides fragilis encoding DNA gyrase
    Onodera, Y
    Sato, K
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) : 2423 - 2429
12